These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. Sain NM; Liang A; Kane SA; Urban MO Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975 [TBL] [Abstract][Full Text] [Related]
9. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. Pol O; Murtra P; Caracuel L; Valverde O; Puig MM; Maldonado R Neuropharmacology; 2006 Jan; 50(1):123-32. PubMed ID: 16360182 [TBL] [Abstract][Full Text] [Related]
10. Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Mikics E; Vas J; Aliczki M; Halasz J; Haller J Behav Pharmacol; 2009 May; 20(3):265-72. PubMed ID: 19421027 [TBL] [Abstract][Full Text] [Related]
11. [Characteristics of effects of mu-, delta-, and kappa-opioid agonists and enkephalinase inhibitor RB101 in rats of two inbred strains]. Sudakov SK; Liupina IuV; Medvedeva OF; Tiurina IV; Maldonado R Biull Eksp Biol Med; 1998 May; 125(5):551-4. PubMed ID: 9644557 [No Abstract] [Full Text] [Related]
12. Differential regulation of morphine antinociceptive effects by endogenous enkephalinergic system in the forebrain of mice. Chen TC; Cheng YY; Sun WZ; Shyu BC Mol Pain; 2008 Sep; 4():41. PubMed ID: 18826595 [TBL] [Abstract][Full Text] [Related]
13. Facilitation of fear extinction by midbrain periaqueductal gray infusions of RB101(S), an inhibitor of enkephalin-degrading enzymes. McNally GP Behav Neurosci; 2005 Dec; 119(6):1672-7. PubMed ID: 16420170 [TBL] [Abstract][Full Text] [Related]
14. Involvement of CB1 cannabinoid receptors in emotional behaviour. Martin M; Ledent C; Parmentier M; Maldonado R; Valverde O Psychopharmacology (Berl); 2002 Feb; 159(4):379-87. PubMed ID: 11823890 [TBL] [Abstract][Full Text] [Related]
15. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650 [TBL] [Abstract][Full Text] [Related]
16. Behavioral effects of the novel cannabinoid full agonist AM 411. McLaughlin PJ; Lu D; Winston KM; Thakur G; Swezey LA; Makriyannis A; Salamone JD Pharmacol Biochem Behav; 2005 May; 81(1):78-88. PubMed ID: 15894067 [TBL] [Abstract][Full Text] [Related]
17. RB101-mediated protection of endogenous opioids: potential therapeutic utility? Jutkiewicz EM CNS Drug Rev; 2007; 13(2):192-205. PubMed ID: 17627672 [TBL] [Abstract][Full Text] [Related]
18. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S Acta Biol Hung; 2007; 58 Suppl():113-29. PubMed ID: 18297798 [TBL] [Abstract][Full Text] [Related]
19. Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. Gorriti MA; Ferrer B; del Arco I; Bermúdez-Silva FJ; de Diego Y; Fernandez-Espejo E; Navarro M; Rodríguez de Fonseca F Pharmacol Biochem Behav; 2005 May; 81(1):71-7. PubMed ID: 15894066 [TBL] [Abstract][Full Text] [Related]
20. Control of hormonal stress reactivity by the endogenous opioid system. Bilkei-Gorzo A; Racz I; Michel K; Mauer D; Zimmer A; Klingmüller D; Zimmer A Psychoneuroendocrinology; 2008 May; 33(4):425-36. PubMed ID: 18280051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]